Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYL1801
- Development stage
- Phase 2
- Lead developer
- Sylentis
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Ophthalmic, Topical
01
Overview
SYL1801 is a chemically modified small interfering RNA (siRNA) developed by Sylentis, a PharmaMar Group company, for the treatment of retinal diseases such as neovascular (wet) age-related macular degeneration (AMD). It is administered as an eye drop solution and works by selectively inhibiting the synthesis of NRARP (Notch-Regulated Ankyrin Repeat Protein), a protein involved in choroidal neovascularization. By downregulating NRARP expression through RNA interference, SYL1801 targets abnormal blood vessel formation in the retina—a key pathological process in wet AMD. Unlike current antiangiogenic therapies that require intravitreal injections, SYL1801 offers a non-invasive topical alternative. The drug has completed Phase I clinical trials and is currently in Phase II development for wet AMD[2][4][7].
- Other names
- syl1801syl-1801syl 1801
02
Targets
NRARP (Notch-regulated ankyrin repeat protein)
Beyond the preview
Go deeper on SYL1801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYL1801.